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Abstract
Sepsis remains a major cause of morbidity and mortality especially in the older individual. In the US alone,
sepsis occurs in approximately 750,000 individuals per year and ranks as the tenth leading cause of death. A major
complication of sepsis is organ failure, with the lung being one of the first organs to fail. Moreover, sepsis is the most
common risk factor for Acute Lung Injury (ALI) and approximately 50% of individuals with sepsis subsequently develop
ALI. Despite its importance, the pathophysiology of sepsis remains unclear. Angiopoietin-2 (Ang-2) is a component of
pathways involved in endothelial survival and maintenance of a quiescent state of the vascular system. The functional
significance of Ang-2 remains to be fully elucidated, but the evidence thus far suggests that it may be key to a better
understanding of the vascular dysfunction and associated organ failure that are so devastating in sepsis. However,
the assessment of the cellular release of Ang-2 is not without difficulty. In this brief review, we discuss the relevance of
Ang-2 to the endothelial dysfunction associated with the severe inflammatory response in sepsis, and why Ang-2 may
not be just a biomarker, but may play a critical role in the pathology. In addition, we discuss some of the reasons why
particular sepsis models may present confusing data with respect to Ang-2 involvement.

Introduction
Sepsis has been recognized since ancient times [1], and the gross
pathology of pulmonary edema in the absence of cardiac insufficiency
was described in the first quarter of the 19th century [2]. Yet, sepsis
and Acute Lung Injury (ALI) remain major sources of morbidity and
mortality especially in the older individual [3-6]. Indeed, approximately
50% of individuals with severe sepsis develop ALI [7,8]. While there
have been significant advances in the treatment of both sepsis and
ALI, particularly in the areas of antimicrobial [9,10], resuscitative
[11-13], and ventilation therapies [14,15], the disappointing lack
of major advances in therapeutic interventions, highlights the need
for a better understanding of the molecular mechanisms underlying
these conditions. Here we examine the altered pulmonary endothelial
activity that results in altered vascular integrity and hemodynamic
instability. Angiopoietin 2 (Ang-2) [16] is a naturally occurring ligand
for the endothelial receptor tyrosine kinase-2(Tie-2) [17]. In view of the
significant correlations of Ang-2 levels with clinical features of sepsis
[18-25], and the characteristic of the Ang/Tie system having control
over vascular system homeostasis [18,26,27], this review will focus on
the importance of Ang-2 in the better understanding of sepsis/ALI
pathophysiology.

Sepsis and Acute Lung Injury
Sepsis is a progressive, injurious, systemic response of the host
to an infection [28]. In the initial response to a local infection, the
interaction with bacterial toxins can drive proximal cells to release
several mediators involved in the proinflammatory response [29-31].
However, the excessive, unrestrained release of these mediators can
result in the development of an overwhelming systemic response,
characteristic of sepsis, leading ultimately to cardiovascular collapse
[32,33]. A common feature of both sepsis and ALI is the development of
increasing vascular leakage leading to extravascular fluid accumulation,
intravascular volume depletion, circulatory and respiratory failure [3436].The failure is due in part to the unresolved lung inflammation that
results in loss of endothelial barrier integrity. These changes lead to an
imbalance between an increased oxygen demand as a result of increased
cellular metabolism, and decreased oxygen transport, resulting from
myocardial depression, and inefficient oxygen extraction due to changes
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in the peripheral microvasculature [37,38]. The respiratory failure tends
to be severe enough to require ventilatory support in approximately
85% of cases [39]. Furthermore, approximately fifty percent of the
septic individuals requiring ventilatory support progress to the acute
respiratory distress syndrome [39]. The mortality associated with ALI is
greater than 38%, and the mortality rate greatly increases as a function
of age [5].
Death in sepsis most likely results from the collective burden of the
sequential failures of organ systems [34,40]. Although the starting points
are the same, simple local infection and complicated sepsis have very
different disease courses. Most simple local infections can be eradicated
by normal functions of the immune system and sometimes with the
help of anti-bacterial [41-43], -viral [44-46], or –fungal [47-49] agents
or thermal interventions [50]. During the disease course, even after
etiologic organisms are controlled, it still takes time until inflammation
resolves. For this process to be successful, an optimal environment
of proper oxygenation and circulation by an intact vasculature is
critical. If it fails, the healing process can be delayed or complicated
as can be seen in patients with diabetes or peripheral vascular disease
who often have chronic non-healing wounds [51,52]. In severe sepsis,
the same principles apply because of the fundamental problem of
the vascular system failure. Systemic inflammation or generalized
vascular inflammation can result in vascular dysfunction. In inflamed
dysfunctional vessels, activated Endothelial Cells (ECs) secrete a variety
of cytokines, recruit immune cells and activate coagulation cascades.
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Most importantly, the vessels are highly permeable. Leaky vessels with
decreased tone not only destabilize the overall hemodynamics, but
also create increased interstitial spaces making oxygen and nutrient
supply to the target tissues difficult. Considering the vascular system
as one big web of highways to every single cell in the body, it is not
surprising that any organ can be affected and eventually fail in sepsis, in
a state of global vascular inflammation and dysfunction. This is one of
the reasons why it is difficult to predict the efficacy of any medication
given in sepsis. In short, sepsis is a life-threatening disease because it
is a state of systemic vascular inflammation. It can involve any organ
that gets oxygen supply by the vascular system which means all organs
in the body are potentially vulnerable in sepsis. Vascular inflammation
and dysfunction makes the healing process fundamentally impaired,
triggering a vicious cycle of worsening inflammation, more organ
damage and dysfunction, ultimately resulting in shock and multiple
organ failure.
There is considerable evidence that microvascular dysfunction is a
critical event in sepsis [53-55]. A major function of the microcirculation
is to provide appropriate oxygen delivery for parenchymal cell
requirements in each organ. In addition, this network of small blood
vessels plays roles in modulation of inflammation and coagulation.
In the healthy state, the microvasculature responds to changes in
both blood flow and metabolic demands. However in sepsis these
functions, which are predominantly controlled by endothelial
cells [56], become dysfunctional [57], and there is evidence that
the endothelium is predominantly a target rather than a source of
systemic inflammation [58]. Furthermore, data from animal and
human studies suggest that improving endothelial function, and in
particular reducing endothelial barrier dysfunction, can significantly
improve sepsis outcome [59,60].
In view of the critical importance of altered endothelial barrier
function during severe sepsis, there is great interest in the factors that
could mediate these changes. In particular, interest has been drawn

to the angiopoietin-Tie2 system, a signaling pathway involved in the
control of microvascular permeability [61,62].

Angiopoietin-2
Ang-2, a molecule implicated in the pathogenesis of critical illness
[63,64], is a member of the Ang/Tie (angiopoietin/tyrosine kinase
with immunoglobulin-like and EGF-like domains) system. The system
consists of four ligands, Ang-1, 2, 3 and 4 and two receptors, Tie-1 and
2. Ang-1 and Ang-2 (both of which bind to Tie-2 [16,65-67] are believed
to be more clinically relevant and better studied than others. Ang- 2
[16] was originally identified from its homology to the angiogenic
factor Angiopoietin-1 (Ang-1), with which it shares significant amino
acid identity [16,68]. Although it was initially recognized for its antiangiogenic properties, over the intervening years much emphasis has
focused on its role in modulating vascular permeability, particularly
in inflammatory lung disease [69], sepsis [19,26,70-72] and acute
lung injury [21,24,25,73]. Furthermore, the simplistic assessment that
Ang-1 is a Tie-2 receptor agonist that phosphorylates and activates
downstream pathways to promote EC survival and maintenance of
the quiescent state of the vascular system; and that Ang-2 antagonizes
Ang-1 activity to increase apoptosis, inflammation and subsequently
endothelial permeability, is somewhat limited. Recent studies suggest
that Ang-2 has complex, context-dependent variable actions which
remain somewhat ill-defined [26,27]. Figure 1 shows the effects of Ang/
Tie-2 interactions on endothelial permeability.

Angiopoietin-2 and the Weibel-Palade Body
Ang-2 is synthesized and stored, primarily, in endothelial cellspecific organelles (known as Weibel-Palade bodies (WPB)) which can,
in the presence of various inflammatory stimuli, be released rapidly
by exocytosis [74,75]. The dynamics and plasticity of WPB have been
reviewed previously by Rondaij et al. [74]. The WPB also contain other
proteins including von Willebrand factor (VWF) [76], endothelin
[77], interleukin-8 [78], p-selectin [79], and tissue-type plasminogen

Figure 1: Permeability change by induced secretion of Ang-2: opposing effects depending on different secretary agonists.
A. Although epinephrine induces WBP exocytosis, thus Ang-2 secretion, it rather decreases EC permeability by a direct effect on Rac1 activation mediated by cAMPPKA pathway. B. Thrombin induces increased EC permeability by PLC-Ca2+ mediated Ang-2 exocytosis which results in RhoA activation. C. Thrombin, in the presence
of protein C in EPCR, induces decreased EC permeability mediated by Gi protein-PI3K-Akt and/or transactivation of S1P1 and by increasing expression of Ang-1Tie-2, subsequently resulting in Rac1 activation. Gs, Gq, Gi, G protein –coupled receptors; AC, adenylyl cyclase; PKA, protein kinase A; PLC, phospholipase C; PIP2,
phosphatidylinositol biphosphate; IP3, inositol (1,4,5) triphosphate; CaM, calmodulin; EPCR, endothelial protein C receptor; S1P1, sphingosine 1-phosphate receptor;
PI3k, phosphatidylinositol 3-kinase; Akt [74,141].
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activator (t-PA) [80]. However, many of the components of the WPB
are not unique to this organelle and are also stored elsewhere in the
cell [81,82]. Therefore while many of the endothelial cell proteins
stored in the WPB may be secreted together from endothelial cells by
both constitutive and regulated secretion [74], their release may also
be induced separately [83]. The situation is further complicated by the
substantial heterogeneity of endothelial cells from different sources,
even from a single organ [84-86]. Thus, the structure and function
of the microcirculation differs between organs and depends upon the
function of that organ [87]. Similarly the endothelial cells that line
the vessels are not homogeneous throughout the cardiovasculature.
There is heterogeneity between micro- and macro-vascular endothelial
cells as well as between microvascular endothelial cells from different
vascular beds [88]. They are morphologically different (continuous,
fenestrated, and discontinuous) and have structural differences related
to macromolecular transport between blood and tissues [85]. This is
perhaps exemplified by the presence or absence of WPB [89].
Understanding WPB exocytosis-mediated Ang-2 secretion is very
important in studying sepsis for many reasons. First, it is known that
various bacterial compounds induce WPB exocytosis, so it is highly
likely that in the septic state there is a high degree of WPB activation
[90,91]. Second, in addition to Ang-2, WPB contains many molecules
involved in inflammation and coagulation pathways including VWF,
P-selectin and t-PA [74,92], although the effects of these molecules
are not limited to either inflammation or coagulation. For example,
VWF is an important mediator of coagulation, but it is also known to
promote leukocyte extravasation [93]. Thus, uncontrolled activation of
the inflammatory and coagulant pathways associated with sepsis could
be explained by endothelial activation and rapid deposition of WPB
contents into the blood stream.
Since the storage and release of Ang-2 is complex, there are many
issues to be considered in regard to Ang-2 activity, including release,
plasma accumulation, and the presence of other mediators. Each of
these areas has been studied, and the data obtained may sometimes
appear conflicting. Some of the studies are outlined below, and some
limitations of the types of studies discussed.

Clinical Studies
Of the many markers of endothelial activation known to be
elevated in sepsis [94,95] Ang-2 is a useful marker of organ dysfunction
and mortality in severe sepsis [72,96-98]. In addition, four studies
illustrate the possible importance of Ang-2 as a marker in sepsis.
First, a prospective clinical study of 61 septic patients found Ang2 concentrations to have a positive linear relationship with plasma
TNF-α and IL-6 concentrations as well as the severity of sepsis assessed
by Acute Physiology and Chronic Health Evaluation (APACHE) II and
Sequential Organ Failure Assessment (SOFA) scores [99] . Second, in
a study of 124 individuals, Ang-2 was elevated in sepsis and correlated
with plasma IL-6 concentration but not TNF-α which was below the
assay lower limit of detection in most cases [100]. In this study, Ang2 correlated with organ failure. The study also revealed increased
Ang-2 concentrations to be related to decreased reactive hyperaemiaperipheral arterial tonometry (RH-PAT), a measure of nitric oxide
bioavalability. The authors suggested that the decreased bioavalability
of nitric oxide may be directly involved in the increased, extracellular accumulation of Ang-2. Third, in 9 recent randomized trial
of 931 patients with ALI, compared to VWF, Ang-2 had a differential
prognostic value for mortality depending on the infection status and the
levels were affected by the type of fluid therapy suggesting its specificity
as a marker of overall vascular status and sepsis pathophysiology [23].
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The fourth report describes a prospective, observational study carried
out at a tertiary care center pediatric intensive care unit [101]. The
authors of the study measured both plasma Ang-1 and Ang-2 and
showed that the Ang-2/1 ratio was elevated in the first three days of
sepsis, with the peak at day 2.
In spite of the close correlation between disease severity and serum
level, whether Ang-2 is a marker of disease or one of the important
etiologic factors in disease progression, remains unclear. In addition,
although increased levels can give clues to possible mediators of the
disease, they do not necessarily explain the mechanisms involved. Thus,
if Ang-2 is a mere marker of endothelial dysfunction or a critical factor
to the disease pathogenesis remains to be fully elucidated.

In vivo Animal Studies
In vivo studies reveal data consistent with the earlier concept of Ang1 and Ang-2 as simple agonist and antagonist, respectively. To evaluate
the interactions, the expression of Ang-1 and -2 has been manipulated
in murine models. These studies show that Ang-1-overexpressing
mice are resistant to vascular leakage caused by inflammatory agents
[102], while Ang-2 knockout mice have impaired leukocyte adhesion
to activated endothelial cells in response to TNF-α [103]. In addition,
mice genetically deficient in Ang-2 showed decreased vascular leakage
in response to histamine, bradykinin or VEGF administration [104].
Consistent with these findings, Ang-2 heterozygous mice develop
less vascular inflammation, organ dysfunction and superior survival
in cecal ligation and puncture sepsis model [105]. In addition,
overexpression of Ang-2 in mice resulted in a sepsis-like phenotype
including hyperpermeability, hypercirculatory hypotension, cardiac
hypertrophy, and fibrosis which are prevented by increasing Ang-1 or
inhibiting Ang-2 [106]. Other investigators have taken the approach
of evaluating the effects of injecting exogenous Ang-2. Local injection
of recombinant Ang-2 induces rapid edema formation in the mouse
paw in a dose-dependent manner peaking at 30 min and resolving
by 4 h [107]. However, systemic administration of Ang-2 induces
vascular hyper-permeability and pulmonary congestion within 3 hours
which progresses over 48 hours in a dose dependent manner [108].
Furthermore, in a mouse model, blocking Ang-2 exocytosis is associated
with improved pulmonary function following Gram-positive challenge
[109]. Lomas-Neira et al. [110] have also investigated a “two-hit” model
of indirect-acute lung injury induced by hemorrhagic shock and sepsis
[110]. The authors showed that Ang-2 was elevated in this model, and
that direct interactions between neutrophils and the endothelium
significantly contributed to the extracellular accumulation of Ang-2.
Importantly, they found that suppression of Ang-2 activity by injecting
the mice intravenously with an siRNA targeting Ang-2 production,
decreased inflammatory lung injury, neutrophil recruitment, and the
plasma concentrations of both IL-6 and TNFα.
Based on these results, elevated Ang-2 levels shown in clinical
studies are consistent with Ang-2 as a pro-inflammatory and
permeability inducing factor. However, some in vitro studies raise
questions challenging this concept.

In vitro studies
VWF and Ang-2 are co-localized within WPB and are depleted
concurrently within 15 min upon uric acid stimulation of HUVEC
[111]. However, peptidoglycan, a component of the bacterial cell wall,
induces secretion of VWF selectively, and not that of Ang-2 [112]. This
implies that for each specific stimulus of WPB exocytosis, there may
be different molecules co-secreted which could affect the final action.
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Second, although t-PA is known to be stored in WPB, at least one
study showed that VWF and t-PA are stored separately, VWF in large
tubular WPB and t-PA in smaller discrete punctate structures [92]. The
authors demonstrated many different sizes of granules going through
exocytosis along with WPB with variable thresholds of activation in
response to stimulation. WPB can also be exocytosed without exogenous
stimulation [113]. Other studies show that there is constitutive release
of Ang-2 into cell culture medium even in the absence of defined
stimulation [114,115]. Taken together, the data suggest that it is
highly possible that Ang-2 is stored not only in WPB but also in other
secretary granules that can have a variety mechanisms of release. One
interesting finding, revealed by electrophysiological studies of WPB
exocytosis, is that calcium induced exocytosis is accompanied by active
endocytosis, especially after an initial rapid exocytosis phase [113]. If
endocytosis overrides exocytosis, this may explain the phenomenon of
certain situations where there is a decrease, rather than an increase, in
extracellular Ang-2 level in culture medium after stimulation [114].

Permeability Change by Manipulation of Tie-2 Receptor
Transfection of endothelial cells with Tie-2 specific siRNA
significantly increases the permeability of the EC layer [108,115]. This
suggests that Ang-1 has a protective effect on cell layer permeability.
However, it does not necessarily offer any useful information regarding
an Ang-2 effect on cell permeability, since Ang-2 effects on Tie-2
receptor are variable and context-dependent [116].
Ang-2 is synthesized and secreted by ECs, and acts on Tie-2 in
an autocrine manner [16,117]. On the other hand, Ang-1, which is
believed to occupy the same receptor, and result in phosphorylation of
Tie-2 when vessels are in a quiescent state, is synthesized and secreted
by pericytes and smooth muscle cells. Studies of the effects of on Tie-2
receptor phosphorylation indicate that Ang-1 alone can induce Tie-2
phosphorylation at 15 and 30 min, and that Ang-2 blocks this response.
However, Ang-2 alone does not change the Tie-2 phosphorylation state
[114]. Other studies have shown that high concentrations of Ang-2
itself can lead to Tie-2 phosphorylation. Additionally, Ang-2 initiation
of the pathways activated downstream of Tie-2 phosphorylation are
slightly different from those activated by Ang-1 [118]. Overall, the

data suggest that Ang-2 has an antagonistic effect against Ang-1-Tie-2
interaction rather than against the Tie-2 receptor itself, and that Tie-2
phosphorylation status is not a single confirmatory marker to show the
activity of Ang-2.
Permeability Changes Induced by Direct Addition of
Recombinant Ang-2
For reasons similar to those discussed previously, studies of the effect
of recombinant Ang-2 on permeability are not simple to interpret. One
study showed that addition of neither Ang-2 nor Ang-1 affects the basal
passage of Horseradish Peroxidase (HRP) or Transepithelial Electrical
Resistance (TEER) at concentrations ranging from 5 to 400 ng/ml at
30min to 5 hours in human pulmonary microvascular endothelial
cells (HPMVEC) [114]. In this study the authors observed that Ang-1
enhanced the basal activity of Rac1 and Ang-2 had a statistically nonsignificant opposite trend to reduce the activity. However, a study by
Parikh et al. [108] showed recombinant Ang-2 (100ng/ml) induces
thick actin stress fibers and intercellular gap formation and increases
permeability measured by FITC-labeled albumin passage in human
microvascular endothelial cells (HMVECs, from neonatal dermis)
[108]. Although the results from the second study may seem to be
more reflective of the in vivo and clinical situation, considering the cell
type used, the study of van der Heijden may be more relevant to sepsis
pathophysiology (Figure 2).

Limitations of in vitro Systems for the Study of Ang-2
Endothelial cells are known to be highly heterogeneous [117,119].
Even among the same cell types, WPB content depends on the passage
number and the state of confluence [113]. WPB may not be observed
in newly plated endothelial cells until after at least 24h. Thereafter, the
numbers of WPB per cell may increase to reach a steady level by 4872h. Hence, even if the cells reach confluence, but the culture time
is not long enough for the cells to develop mature WPB (to produce
a burst reaction in response to stimulus), the same stimulus could
induce different results. In addition, isolated EC culture systems are not
ideal to study the Ang/Tie-2 system because there are no pericytes or
smooth muscle cells which are the physiologic sources of Ang-1 and
natural environments of the system. It is known that ECs and mural

Figure 2: Manipulating endothelial permeability.
A. Ang-1 has a protective effect on cell layer permeability. siRNA transfection of Tie-2 has an opposite effect on permeability. B. Direct addition of recombinant Ang-2
induces increased permeability showing the antagonistic effect of Ang-2 on Ang-1-Tie-2 induced protective effect on permeability.
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cells are highly interactive [120-123]. As a result, in monocultures,
critical factors, including Ang-1, are missing, which could confound
the assessment of Ang-2 effects. Thus, it is reasonable to consider
co-cultures or pre-treatment with Ang-1 for in vitro studies of Ang/
Tie-2 system. In addition, ECs are known to communicate with other
hematopoietic cells[124], and there is evidence suggesting that EC Ang2 may recruit Tie-2 positive monocytes to inflammatory sites [125]. This
being the case, it is highly likely that in sepsis ECs actively communicate
with other inflammatory cells. Thus, studying EC-inflammatory cell
communication could also give new insights into the role of the Ang/
Tie-2 system.
There are many artificial environmental factors that can potentially
affect study results of in vitro culture systems. For example, it is known
that WPB exocytosis is affected by pH [126] and Ang-2 expression is
up regulated by hyperoxia [127]. To complicate the situation further,
in vitro culture conditions, do not reflect the physiological conditions
and the generally accepted culture terminology can be misleading. For
example, the terms, “normoxic” and “hypoxic” conditions used in cell
culture [128] may not be representative of the in vivo situations. Cell
cultures are conventionally maintained with the oxygen level equivalent
to that of room air (approx 20% oxygen). While this is normally
referred to as “normoxic”, it is not the physiologic environment that
cells would experience in vivo. In addition, the oxygen concentration
at the cellular level in static in vitro culture changes greatly depending
on the amount of culture medium and the cell number [129-134]. Since
hypoxia is a known triggering factor of WPB exocytosis [135] and Ang2 dynamics are affected by both hypoxia and hyperoxia, the effect of
significantly different oxygen levels generated by slight differences in
cell culture environment should not be ignored. In addition, there are
other unanswered fundamental questions in cell culture systems. There
is consensus that the passage number of primary cells should be kept
low so that they are studied before possible changes in phenotype [136].
However, during the processes of cell isolation and freeze- thawing,
the cells are subject to considerable stress. The rate of cell replication,
intracellular pathway activation, secretion of cytokines, and the
expression of the surface molecules can be altered as a result of this
stress [137-140]. Thus, it is often difficult to assess which cell phenotype
best reflects the in vivo situation. Clearly, in vitro cultures only model the
in vivo situation. However, efforts to isolate and minimize confounding
factors are essential especially in a system as complicated, dynamic,
and inter-dependent as Ang/Tie-2-WPB. As in many systems, due to
dynamic interactions, no one molecule can be examined separately and
efforts should be made to compensate for the deficient conditions.

Conclusion
Multiple clinical studies have consistently shown close correlation
between Ang-2 level and sepsis severity and its pulmonary sequelae.
Thus, Ang-2 is most likely an important mediator, or at least a clear
marker of disease severity, in sepsis pathophysiology. So far, in vitro
studies have shown that Ang-2 induces or enhances EC permeability
in a context dependent manner and in vivo and clinical studies suggest
Ang-2 as a powerful permeability inducing factor. Taken together,
Ang-2 is most likely an effective permeability triggering or enhancing
factor only in the presence of other cofactors normally present in
physiologic conditions. This makes the mechanisms involved in Ang/
Tie-2 interactions key to a better understanding of the pathogenesis of
sepsis and its pulmonary sequelae. It also makes the Ang/Tie-2 system
an interesting therapeutic target to improve tissue oxygenation and
hemodynamics, and significantly alter the pathological course of sepsis.
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